Oncology and Hematology News and Journal Articles
By Leslie Padrnos and Ruben A. Mesa
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
A phase III trial failed to demonstrate superiority of eribulin over treatment of physician’s choice in patients with heavily pretreated non–small-cell lung cancer.
A lower dose of rabbit anti–T-lymphocyte globulin was superior to a higher dose in children with hematologic malignancies undergoing transplant from an unrelated donor.
Adherence to screening protocols at cancer centers resulted in fewer emergency department visits and hospitalizations in the 2-month period after the screening.
The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer.
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab.
This slide show presents tricks for surviving and thriving at the ASCO Annual Meeting in Chicago. Everything from transportation, McCormick Place, planning your days, using social media, which sessions to attend, how to network, where to eat, and how to be a tourist in Chicago.
The journal ONCOLOGY includes a cartoon at the end of each issue. Here are the collected cartoons to date.